Quarterly ResultMay 8, 2026, 07:12 AM
Kiora Pharmaceuticals Q1 Net Loss $(2.4M); Secures $5M Equity Financing
AI Summary
Kiora Pharmaceuticals reported a Q1 2026 net loss of $(2.4) million, or $(0.58) per share, and ended the quarter with $13.9 million in cash and short-term investments. Subsequent to the quarter, the company secured a $5.0 million strategic equity financing, extending its operational runway into late 2028. The company also provided updates on its clinical programs, noting active enrollment in the Phase 2 ABACUS-2 study for KIO-301 with trial site expansion, and continued progress in the Phase 2 KLARITY study for KIO-104.
Key Highlights
- Secured $5.0 million in strategic equity financing subsequent to quarter end.
- Extended operational runway into late 2028, beyond anticipated clinical data readouts.
- Ended Q1 2026 with $13.9 million in cash and short-term investments.
- Reported Q1 2026 net loss of $(2.4) million, compared to $(2.2) million in Q1 2025.
- Basic net loss per common share was $(0.58) for Q1 2026, vs $(0.52) in Q1 2025.
- Research and development expenses were $2.1 million in Q1 2026, down from $2.5 million.
- ABACUS-2 study for KIO-301 has close to 50% enrollment completed.